论文部分内容阅读
目的观察恩替卡韦联合肝复胶囊治疗乙型肝炎肝硬化的临床疗效。方法将72例乙型肝炎肝硬化随机分成两组,治疗组(42例)接受恩替卡韦联合肝复胶囊治疗;对照组(30例)单纯接受恩替卡韦治疗。疗程均为9个月。观察治疗前后丙氨酸转氨酶(ALT)复常率、HBe Ag阴转率、HBV DNA检测不到率及肝纤维化等指标的变化情况。结果治疗9个月后治疗组肝功能指标复常率明显高于对照组,治疗组ALT(25.60±35.82)U/L,TBIL(18.82±9.76)μmol/L;对照组ALT(45.57±44.42)U/L,TBIL(24.33±12.14)μmol/L,两组对比,P<0.05。血清肝纤维化指标亦有明显改善,治疗组HA(197.4±32.4)LN(65.7±34.7)PCⅢ(102.2±17.2)IV-C(89.4±14.2),对照组HA(327.8±51.7)LN(92.4±36.5)PCⅢ(181.3±25.5)IV-C(132.4±2.7),两组对比,P<0.05。结论恩替卡韦联合肝复胶囊治疗乙型肝炎肝硬化疗效优于恩替卡韦单一用药。
Objective To observe the clinical efficacy of entecavir and liver capsule in the treatment of hepatitis B cirrhosis. Methods Seventy-two patients with hepatitis B cirrhosis were randomly divided into two groups. The treatment group (n = 42) received entecavir plus Ganfukang capsule. The control group (n = 30) received entecavir alone. Treatment are 9 months. The changes of alanine aminotransferase (ALT) normalization rate, HBeAg negative conversion rate, HBV DNA undetectable rate and liver fibrosis were observed before and after treatment. Results After treatment for 9 months, the recovery rate of liver function index in the treatment group was significantly higher than that in the control group (ALT: 25.60 ± 35.82 U / L, TBIL: 18.82 ± 9.76 μmol / L, ALT: 45.57 ± 44.42, U / L, TBIL (24.33 ± 12.14) μmol / L, the two groups were compared, P <0.05. Serum levels of serum fibrosis were significantly improved in the treatment group as compared with those of the control group (197.4 ± 32.4 LN vs 65.7 ± 34.7 PC Ⅲ 102.2 ± 17.2 IV-C 89.4 ± 14.2, and 327.8 ± 51.7 LN vs 92.4 ± 36.5) PCⅢ (181.3 ± 25.5) IV-C (132.4 ± 2.7), P <0.05. Conclusion The efficacy of entecavir and liver capsule in the treatment of hepatitis B cirrhosis is better than that of entecavir alone.